Clinical efficacy and safety of hyperthermic intraperitoneal perfusion chemotherapy after cytoreductive surgery for ovarian carcinoma: a meta-analysis

Abstract

Objective To analyze the clinical efficacy and safety of hyperthermic intraperitoneal perfusion chemotherapy (HIPC) after cytoreductive surgery for ovarian carcinoma.Methods Based on the pre-designed criteria,the articles published were searched and recorded for data on types and options of surgery,use of HIPC,complications,mortalities,hospital stays and survival time.The dosage of chemotherapy agents,method of hyperthermic perfusion and duration of chemotherapy were also described.Results Fourteen articles were finally included in this meta-analysis.Among these,7 studies showed favorable patient outcomes with HIPC after radical tumor resection.The median survival time and median disease-free survival for primary ovarian carcinoma and relapsed ovarian carcinoma ranged from 22 to 54months and 10 to 26 months,respectively.The incidence of serious complications with HIPC after cytoreductive surgery ranged from 5％ to 36％,with the median mortality being 3％ (0％ -10％ ).The incidence of complications and the mortality were low.Conclusion HIPC after cytoreductive surgery may be used as a promising treatment which is clinically safe and feasible. Key words: Ovarian neoplasms; Treatment outcome; Meta-analysis; Cytoreductive surgery; Hyperthermic intraperitoneal perfusion chemotherapy